title: Effects of polysulfated glycosaminoglycan on chemical and physical defects in equine articular cartilage.
abstract: The effect of intra-articular polysulfated glycosaminoglycan (PSG) on repair of chemical and physical articular cartilage injuries was evaluated in 8 horses. In each horse, a partial- and a full-thickness articular cartilage defect was made on the distal articular surface of the radial carpal bone. In the contralateral middle carpal joint, a chemical articular cartilage injury was induced by injecting 50 mg of Na monoiodoacetate (MIA). Four of the 8 horses were not treated (controls), and 4 horses were treated by intra-articular injection of 250 mg of PSG into both middle carpal joints once a week for 5 treatments starting 1 week after cartilage injury. Horses were maintained for 8 weeks. There was less joint circumference enlargement in PSG-treated horses in MIA-injected and physical defect carpi, compared with that in controls. In MIA-injected joints, there was less articular cartilage fibrillation and erosion, less chondrocyte death, and greater safranin-O staining for glycosaminoglycans in PSG-treated horses. Evaluation of joints in which physical defects were made revealed no differences between control and PSG-injected joints. None of the partial-thickness defects had healed. Full-thickness defects were repaired with fibrous tissue (which was more vascular and cellular in PSG-injected joints) and occasionally small amounts of fibrocartilage. Seemingly, PSG had chondroprotective properties in a model of chemically induced articular cartilage damage, whereas PSG had no obvious effect in a physical articular cartilage-defect model.
authors: Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins 80523.
authors: J V
authors: JV
authors: Yovich
authors: G W
authors: GW
authors: Trotter
authors: C W
authors: CW
authors: McIlwraith
authors: R W
authors: RW
authors: Norrdin
mesh_terms: D000818:Animals; D002350:Carpus, Animal / Q000293:injuries* / Q000473:pathology; D002357:Cartilage Diseases / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D002358:Cartilage, Articular / Q000293:injuries* / Q000473:pathology; D005552:Forelimb / Q000293:injuries*; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006734:Horse Diseases / Q000188:drug therapy* / Q000473:pathology; D006736:Horses; D007794:Lameness, Animal / Q000188:drug therapy*
chemical_list: D006025:Glycosaminoglycans; C013786:A73025